Brain Cancer
Callisto Pharmaceutical's Degrasyn class has potential to treat brain tumors
Published in Cancer Weekly, February 20th, 2007
STAT3 pathway inhibitors are a new class of drugs that were licensed to Callisto Pharmaceuticals from The University of Texas M. D. Anderson Cancer Center. The report, published in the journal Oncogene, describes studies with WP1066 on human malignant glioma (brain tumor) cells and in a mouse model of human brain cancer. Notably, WP1066 administered to mice significantly inhibited the growth...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-02-20)
More Articles from Cancer Weekly
- Cancer Therapy
Prostate cancer patients see high survival rates with seed implants - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at Harbin Medical University, Department of General Surgery - Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at Baylor College of Medicine, Scott Department of Urology - Cancer Gene Therapy
Data on cancer gene therapy published by researchers at Massachusetts General Hospital - Cancer Gene Therapy
Findings from Chang-Gung University, Graduate Institute of Basic Medical Science provide new insights into cancer gene therapy - Cancer Gene Therapy
New cancer gene therapy findings from National Cancer Institute, Division of Cancer Prevention published - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
